Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo

Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1), which actively extrudes chemotherapeutic agents from cells and significantly decreases the efficacy of chemotherapy, is viewed as a major obstacle in osteosarcoma chemotherapy. Anlotinib, a novel tyrosine kinase...

Descrizione completa

Dettagli Bibliografici
Autori principali: Gangyang Wang, Lingling Cao, Yafei Jiang, Tao Zhang, Hongsheng Wang, Zhuoying Wang, Jing Xu, Min Mao, Yingqi Hua, Zhengdong Cai, Xiaojun Ma, Shuo Hu, Chenghao Zhou
Natura: Articolo
Lingua:English
Pubblicazione: Frontiers Media S.A. 2022-01-01
Serie:Frontiers in Pharmacology
Soggetti:
anlotinib
osteosarcoma
multidrug resistance
ATP-binding cassette (ABC) transporter
P-glycoprotein
Accesso online:https://www.frontiersin.org/articles/10.3389/fphar.2021.798837/full

Accesso online

https://www.frontiersin.org/articles/10.3389/fphar.2021.798837/full

Documenti analoghi